JP2005538701A5 - - Google Patents

Download PDF

Info

Publication number
JP2005538701A5
JP2005538701A5 JP2004502947A JP2004502947A JP2005538701A5 JP 2005538701 A5 JP2005538701 A5 JP 2005538701A5 JP 2004502947 A JP2004502947 A JP 2004502947A JP 2004502947 A JP2004502947 A JP 2004502947A JP 2005538701 A5 JP2005538701 A5 JP 2005538701A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004502947A
Other languages
English (en)
Japanese (ja)
Other versions
JP4557714B2 (ja
JP2005538701A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/015044 external-priority patent/WO2003094859A2/en
Publication of JP2005538701A publication Critical patent/JP2005538701A/ja
Publication of JP2005538701A5 publication Critical patent/JP2005538701A5/ja
Application granted granted Critical
Publication of JP4557714B2 publication Critical patent/JP4557714B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004502947A 2002-05-10 2003-05-12 ＥｐｈＡ２モノクローナル抗体およびその使用法 Expired - Fee Related JP4557714B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37932202P 2002-05-10 2002-05-10
US41821302P 2002-10-14 2002-10-14
US46050703P 2003-04-03 2003-04-03
PCT/US2003/015044 WO2003094859A2 (en) 2002-05-10 2003-05-12 Epha2 monoclonal antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010115398A Division JP2010246546A (ja) 2002-05-10 2010-05-19 ＥｐｈＡ２モノクローナル抗体およびその使用法

Publications (3)

Publication Number Publication Date
JP2005538701A JP2005538701A (ja) 2005-12-22
JP2005538701A5 true JP2005538701A5 (enExample) 2008-07-03
JP4557714B2 JP4557714B2 (ja) 2010-10-06

Family

ID=29424523

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004502947A Expired - Fee Related JP4557714B2 (ja) 2002-05-10 2003-05-12 ＥｐｈＡ２モノクローナル抗体およびその使用法
JP2010115398A Pending JP2010246546A (ja) 2002-05-10 2010-05-19 ＥｐｈＡ２モノクローナル抗体およびその使用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010115398A Pending JP2010246546A (ja) 2002-05-10 2010-05-19 ＥｐｈＡ２モノクローナル抗体およびその使用法

Country Status (8)

Country Link
US (3) US20040028685A1 (enExample)
EP (1) EP1519956B1 (enExample)
JP (2) JP4557714B2 (enExample)
AT (1) ATE525398T1 (enExample)
AU (2) AU2003243228B2 (enExample)
CA (1) CA2485373A1 (enExample)
ES (1) ES2373715T3 (enExample)
WO (1) WO2003094859A2 (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
ATE525398T1 (de) * 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
JP2006501153A (ja) 2002-05-23 2006-01-12 パーデュー・リサーチ・ファウンデーション 診断及び治療用標的としての低分子量タンパク質チロシンホスファターゼ（ｌｍｗ−ｐｔｐ）
EP1606305A4 (en) 2003-03-12 2009-06-24 Vasgene Therapeutics Inc NUCLEIC ACID COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
KR20110094361A (ko) * 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US20050049176A1 (en) * 2003-04-11 2005-03-03 Kiener Peter A. EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
WO2004091375A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
US8012681B2 (en) * 2003-05-13 2011-09-06 Novartis Vaccines And Diagnostics, Inc. Methods of modulating metastasis and skeletal related events resulting from metastases
US20050147593A1 (en) * 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
WO2005048917A2 (en) 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
CA2531069A1 (en) * 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
JP2007528723A (ja) * 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
CN1905899B (zh) * 2003-11-20 2011-09-28 医学免疫公司 EphA2激动性单克隆抗体及其使用方法
WO2005056766A2 (en) * 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES
US20050153923A1 (en) * 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
EP1732580A4 (en) * 2003-12-24 2008-01-23 Medimmune Inc EPHA2 VACCINES
DE102004010050A1 (de) * 2004-03-02 2005-09-22 Bayer Healthcare Ag Spezifische monoklonale und polyklonale Antikörper für Repinotan und dessen ringoffene Form
EP2275445A3 (en) 2004-03-12 2012-02-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
DE602005025459D1 (de) 2004-03-12 2011-02-03 Vasgene Therapeutics Inc Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
CA2561513C (en) 2004-03-29 2019-02-26 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
EP1755673B1 (en) 2004-04-12 2014-07-23 MedImmune, LLC Anti-il-9 antibody formulations and uses thereof
US20060019342A1 (en) * 2004-06-25 2006-01-26 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
AU2005277641A1 (en) * 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
AU2005295158A1 (en) * 2004-10-18 2006-04-27 Medimmune, Llc High cell density process for growth of Listeria
JP2008518207A (ja) * 2004-10-21 2008-05-29 ザ ペン ステート リサーチ ファウンデーション Ｅｐｈ受容体腫瘍バイオマーカー
CA2585671A1 (en) * 2004-10-27 2006-05-04 Medimmune, Inc. Use of modulators of epha2 and ephrina1 for the treatment and prevention of infections
WO2006047639A2 (en) * 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20060122138A1 (en) * 2004-10-27 2006-06-08 Medimmune, Inc. Modulators of EphA2 and EphrinA1 for the treatment of fibrosis-related disease
WO2006113679A2 (en) * 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions
KR101363252B1 (ko) 2005-02-04 2014-02-13 레이븐 바이오테크놀로지스, 인코퍼레이티드 Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
UA90909C2 (en) * 2005-07-20 2010-06-10 Мерк Шарп Энд Домэ Корп. Hcv ns3 protease inhibitors
AU2006287416A1 (en) * 2005-09-07 2007-03-15 Medimmune, Llc Toxin conjugated Eph receptor antibodies
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US7803364B2 (en) 2005-11-17 2010-09-28 The Cleveland Clinic Foundation Multipotent neural stem cells
EP1968998A4 (en) * 2005-12-21 2010-01-27 Medimmune Llc AFFINITY-OPTIMIZED EPHA2-AGONISTIC ANTIBODIES AND METHODS FOR THEIR USE
EA020324B1 (ru) 2006-07-18 2014-10-30 Санофи-Авентис АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
KR20100056438A (ko) * 2007-06-18 2010-05-27 메디뮨 엘엘씨 ＥｐｈＡ2 및 ＥｒｂＢ2를 발현하는 세포의 상승적 치료 방법
CA2691785C (en) 2007-06-27 2017-01-10 Marine Polymer Technologies Inc. Complexes of il-15 and il-15ralpha and uses thereof
AU2008287427B2 (en) 2007-08-13 2014-10-09 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to EphB4
SI2199390T1 (sl) * 2007-08-30 2017-02-28 Daiichi Sankyo Company, Limited Proti-epha2 protitelo
JP5785490B2 (ja) 2008-04-02 2015-09-30 マクロジェニクス，インコーポレーテッド Ｂｃｒ複合体特異的抗体およびその使用方法
WO2010127181A1 (en) 2009-04-29 2010-11-04 Trellis Bioscience, Inc. Improved antibodies immunoreactive with heregulin-coupled her3
AU2010282340B2 (en) 2009-08-13 2016-12-22 The Johns Hopkins University Methods of modulating immune function
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
WO2012012759A2 (en) 2010-07-22 2012-01-26 The Regents Of The University Of California Anti-tumor antigen antibodies and methods of use
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
AU2012216627A1 (en) * 2011-11-14 2013-05-30 Newcastle Innovation Ltd. Composition and methods for the diagnosis, prognosis and treatment of leukemia
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
SG10201913680PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
CA3020864A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
JPWO2018135653A1 (ja) * 2017-01-23 2020-01-09 学校法人 東洋大学 抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出
JP7132232B2 (ja) 2017-02-24 2022-09-06 マクロジェニクス，インコーポレーテッド Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
EP3768719A4 (en) * 2018-03-19 2022-04-27 Abeome Corporation HIGH AFFINITY NEUTRALIZING ANTIBODIES AGAINST PROGRAMMED DEATH LIGAND 1 (PD-L1) AND THEIR USE
US11505610B2 (en) 2018-04-06 2022-11-22 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
EP3897851A2 (en) 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
EP4031576A1 (en) 2019-09-18 2022-07-27 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
CN114746120B (zh) 2019-10-03 2024-07-30 Atyr医药公司 包含抗nrp2抗体的组合物和方法
JP7745556B2 (ja) 2020-02-21 2025-09-29 マクロジェニクス，インコーポレーテッド Ｃｄ１３７結合分子及びその使用
EP4262858A1 (en) 2020-12-16 2023-10-25 Molecular Templates, Inc. Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector
US12162945B2 (en) 2021-03-05 2024-12-10 Immunome, Inc. EPHA2 antibodies
US20250340655A1 (en) * 2022-05-27 2025-11-06 Taipei Medical University Epha2-targeting antibodies and their applications in cancer treatment
CN116693597B (zh) * 2023-03-09 2024-06-21 南京大学 一种对苯酚衍生物、多肽和蛋白质中酪氨酸进行硝基化的方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31252A (en) * 1861-01-29 Improvement in iron ties for cotton-bales
US4472371A (en) * 1979-10-29 1984-09-18 Summa Medical Corporation Radiolabeled antibody to anti-tumor associated antigen and process
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5001225A (en) * 1986-12-08 1991-03-19 Georgetown University Monoclonal antibodies to a pan-malarial antigen
US4885238A (en) * 1987-10-30 1989-12-05 The United States Of America As Represented By The Department Of Health And Human Services Immortalized human bronchial epitherial mesothelial cell lines
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2096417C (en) * 1991-08-22 2000-10-10 Sarah S. Bacus Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
JP4157160B2 (ja) * 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5837448A (en) * 1992-05-15 1998-11-17 The Salk Institute For Biological Studies Protein-tyrosine kinase genes
US5824303A (en) * 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
AU685765B2 (en) * 1992-11-13 1998-01-29 Amgen, Inc. (Eck) receptor ligands
PT669929E (pt) * 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5516658A (en) * 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US5747033A (en) * 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
US5457048A (en) * 1993-12-03 1995-10-10 La Jolla Cancer Research Foundation Eph-related tyrosine kinases, nucleotide sequences and methods of use
US5814479A (en) * 1994-01-04 1998-09-29 Zhou; Renping Bsk receptor-like tyrosine kinase
AU702522B2 (en) * 1994-04-15 1999-02-25 Amgen, Inc. HEK5, HEK7, HEK8, HEK11, new EPH-like receptor protein tyrosine kinases
US5624899A (en) * 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5795734A (en) * 1994-09-19 1998-08-18 President And Fellows Of Harvard College EPH receptor ligands, and uses related thereto
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US6057124A (en) * 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US5876949A (en) * 1995-05-31 1999-03-02 The Trustees Of The University Of Pennsylvania Antibodies specific for fragile X related proteins and method of using the same
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US5795775A (en) * 1996-09-26 1998-08-18 Becton Dickinson And Company Culture vessel and assembly
US5761934A (en) * 1996-10-22 1998-06-09 Kuo; Li-Tsao Cable lock and an universal hold-down support
US6387615B2 (en) * 1997-04-11 2002-05-14 Isis Innovation Limited Methods and materials for the diagnosis or prognosis of asthma
WO1999008696A1 (en) * 1997-08-19 1999-02-25 Vanderbilt University METHODS FOR DETERMINING CELL RESPONSES THROUGH EphB RECEPTORS
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
US6887674B1 (en) * 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) * 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6696550B2 (en) * 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
ATE293989T1 (de) * 1998-11-20 2005-05-15 Genentech Inc Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
DE60045075D1 (de) * 1999-08-17 2010-11-18 Purdue Research Foundation Anti-epha2 antikörper als krebsdiagnostikum
AU6784400A (en) * 1999-08-17 2001-03-13 Glaxo Group Limited Treatment of metastatic disease
US6245320B1 (en) * 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
US20010031262A1 (en) * 1999-12-06 2001-10-18 Michael Caplan Controlled delivery of antigens
CA2398466A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
AU4002001A (en) * 2000-03-01 2001-09-12 Med Immune Inc High potency recombinant antibodies and method for producing them
NZ521898A (en) * 2000-03-31 2004-11-26 Purdue Research Foundation Use of a ligand-immunogen conjugate such as folate-FITC for enhancing an endogenous immune response
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20030199071A1 (en) * 2000-12-08 2003-10-23 Solomon Langermann Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
JP4336498B2 (ja) * 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
DE60239535D1 (de) * 2001-06-18 2011-05-05 Rosetta Inpharmatics Llc Diagnose und prognose von brustkrebspatientinnen
US7250495B2 (en) * 2001-06-20 2007-07-31 Genentech, Inc. PRO20044 polypeptides
JP2003059182A (ja) * 2001-08-10 2003-02-28 Teac Corp １ビット形式ディジタル信号の記録方法及び記録装置及び付加装置
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
ATE525398T1 (de) * 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
WO2004010935A2 (en) * 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
US7504211B2 (en) * 2002-08-27 2009-03-17 Bristol-Myers Squibb Company Methods of using EPHA2 for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
WO2004028551A1 (en) * 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
WO2004091375A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
JP2007526208A (ja) * 2003-04-11 2007-09-13 メディミューン，インコーポレーテッド 呼吸器の症状を治療又は予防する方法
KR20110094361A (ko) * 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도

Similar Documents

Publication Publication Date Title
JP2006507013A5 (enExample)
JP2005533493A5 (enExample)
RU2421465C2 (ru) Антитела к рецептору igf-i
US9249223B2 (en) Humanized anti CXCR4 antibodies for the treatment of cancer
JP2021514664A5 (enExample)
JP2022513053A (ja) Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用
JP2020534250A5 (enExample)
JP2011157397A5 (enExample)
JP2008529497A5 (enExample)
JP2007504280A5 (enExample)
JP2008529494A5 (enExample)
JP2017538439A5 (enExample)
KR20140027051A (ko) 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체
CN110382533A (zh) 特异性结合CD66c的抗体及其用途
CN112166125A (zh) 全人源的抗lag-3抗体及其应用
CN109414489B (zh) 网蛋白-1结合抗体及其用途
US20220154296A1 (en) Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors
JP2009544574A5 (enExample)
JP2023533793A5 (enExample)
JP2025533015A (ja) 薬物抵抗性肝細胞癌の処置
CN112041346B (zh) 用于与抗pd-1抗体组合的抗cd137抗体
AU2020371040B2 (en) Means and methods for treating subjects with HER2 and HER3 positive cancer
AU2017277288B2 (en) Monoclonal antibodies, compositions and methods for detecting mucin -like protein (MLP) as a biomarker for ovarian and pancreatic cancer
JP2007516226A5 (enExample)
TWI888704B (zh) 抗ｃｄ７３之抗體及其應用